Human blood plasma as source for biotherapeutics is very limited and safety concerns still persist, leading to a growing need for recombinant Plasma Proteins. In addition, glycosylation patterns of most Plasma Proteins are very complex and represent a huge challenge to recombinant protein expression. With a comprehensive portfolio of glyco-optimized human cell lines, the CAP®Go expression system paves the way for recombinant Plasma Proteins.
Recombinant human C1 Inhibitor (C1-INH)
C1-Inhibitor deficiency patients suffer from an inherited form of angioedema which is currently predominantly being treated with intravenous injections of C1 Inhibitor purified from human serum. CEVEC´s CAP®Go derived C1 Inhibitor showed in a pivotal pharmacokinetic rat study a serum half-life matching Berinert®, one of the two currently available, plasma derived treatments. This result, in combination with excellent specific activities of CAP®Go derived C1 Inh and commercially attractive production yields, paves the way to develop a safer and more economic therapy for acute and prophylactic HAE indications.